Ozempic, Wegovy, Mounjaro and Zepbound Heartburn and Acid Reflux: Label Rates, Research and Red Flags
Do Zepbound, Wegovy, Ozempic or Mounjaro cause heartburn or acid reflux? Label trial rates, what large studies found, why slower stomach emptying matters, and red flags.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Yes. Heartburn, acid reflux (gastro-oesophageal reflux disease, GERD) and indigestion (dyspepsia) are listed side effects of tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic). In the weight-loss trials, reflux affected 4% to 5% of people on Zepbound vs 2% on placebo and 5% on Wegovy vs 3%, and indigestion was about three times as common as on placebo. These drugs slow how fast the stomach empties, which is a known risk factor for reflux. A 2025 review of 55 placebo-controlled trials found GLP-1 drugs probably double the risk of a GERD diagnosis, though the extra cases were few. Chest pain, trouble swallowing, vomiting blood or black stools need urgent care. Not medical advice. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Facts checked October 27, 2026.
Reflux and indigestion rates on the US labels
Figures from the placebo-controlled trial data in each US label (Zepbound, Wegovy, Mounjaro, Ozempic, DailyMed, May to August 2026). Where a label lists several strengths, the range covers all of them. Burping is covered on the sulfur burps page.
Why GLP-1 drugs cause heartburn
All four labels say these medicines delay gastric emptying, so food and acid sit in the stomach longer. Delayed emptying is an established risk factor for reflux, which is the reasoning behind the large studies below. Fuller stomachs, burping and nausea can add to it, and the gut side effects are most common while the dose is being increased. Severe, lasting slowing of the stomach is a separate problem: see GLP-1 gastroparesis.
What large studies found
The evidence points the same way, with small absolute numbers:
| Study | What it found |
|---|---|
| Chiang 2025 (Gastroenterology) | Meta-analysis of 55 placebo-controlled trials, 106,395 people: GLP-1 drugs probably increase GERD (risk ratio 2.19), about 4 extra cases per 1,000 people |
| Noh 2025 (Annals of Internal Medicine) | UK records study (senior author at McGill, Montreal) of 24,708 new GLP-1 users with type 2 diabetes vs SGLT-2 inhibitor users: 27% higher GERD risk over 3 years, about 0.7 extra cases per 100 people, and more GERD complications |
| Liu 2024 (Gut) | Global health-records study (TriNetX): higher erosive reflux and Barrett's oesophagus risk with short-acting GLP-1 drugs (exenatide, liraglutide, lixisenatide), but not with long-acting ones |
| Choi 2026 (Gut and Liver) | Reporting study across US, Japanese and Canada Vigilance databases: GERD reported 2 to 5 times more often with GLP-1 drugs than with DPP-4 inhibitors; semaglutide had the strongest signal, then liraglutide and tirzepatide. Shows reporting patterns, not rates |
Is heartburn worse on Zepbound or Wegovy?
The labels are not head-to-head, but the weight-loss trial numbers are close: reflux 4% to 5% on Zepbound and 5% on Wegovy, indigestion 9% to 10% and 9%. A 2025 review of 13 trials (Safwan 2025) found gut side effects overall more frequent on tirzepatide than semaglutide, mostly mild. In Choi 2026, semaglutide had the strongest reporting signal, but reports depend on how widely a drug is used and publicised.
Reflux and anaesthesia
All four labels warn that pulmonary aspiration (stomach contents entering the lungs) has occurred in people on GLP-1 drugs having general anaesthesia or deep sedation. Tell the surgical or endoscopy team you take one before any procedure; whether and when to pause it is their call.
When heartburn is a warning sign
- —Chest pain or pressure, especially with breathlessness, sweating or pain spreading to the arm or jaw: call 911. It may be the heart, not reflux.
- —Trouble or pain swallowing, food sticking, vomiting blood or material like coffee grounds, or black stools.
- —Severe upper stomach pain that may spread to the back: GLP-1 pancreatitis; pain under the right ribs with fever: gallbladder problems.
- —Heartburn most days, or symptoms that wake you at night: tell the prescriber rather than self-treating indefinitely.
In Canada
The Canadian Ozempic product monograph (July 13, 2026) reports reflux in 1.6% to 2.7% and indigestion in 4.1% to 5.2% of people on Ozempic vs 1.0% and 2.1% on comparators. The Canadian Wegovy monograph (October 2, 2026) gives reflux 5.4% vs 3.0% and indigestion 9.0% vs 3.2% in adults, and the Canadian Mounjaro monograph (June 23, 2026) reports reflux in 1.7% to 2.5% vs 0.4% and indigestion in 5.4% to 8.0% vs 2.6%. The Noh 2025 study came from researchers at McGill and the Jewish General Hospital in Montreal, funded by the Canadian Institutes of Health Research, and Choi 2026 found the same signal in Canada Vigilance reports. More: Ozempic side effects in Canada and Mounjaro side effects in Canada.
What users report here
Reflux and heartburn come up in several live confessions (checked October 27, 2026). #308 had reflux for fifteen years; on tirzepatide the first week was rough, then it faded as weight came off. #450 got acidic burps and constant diarrhoea after restarting Mounjaro. On retatrutide, an unapproved triple agonist, #845 calls the heartburn "actual torture", #558 reports bad heartburn, and #411 gets reflux only when eating close to bed. #559 asks whether people with existing reflux and gastritis can take a GLP-1 at all, a question for a prescriber. Stories, not rates.
Related topics
related peptides:
in Canada:
community guides:
More confessions from the archive
Community Q&A
- Does Zepbound cause heartburn or acid reflux?
- Yes. In the Zepbound weight-loss trials, reflux affected 4% to 5% of people vs 2% on placebo, and indigestion 9% to 10% vs 4%.
- Does Wegovy cause heartburn?
- Yes. The Wegovy label reports reflux in 5% vs 3% on placebo and indigestion in 9% vs 3% in adult weight-loss trials.
- Does Ozempic cause acid reflux?
- It can. The US label reports reflux in 1.5% to 1.9% of people with type 2 diabetes vs none on placebo; the Canadian monograph gives 1.6% to 2.7% vs 1.0%.
- Does Mounjaro cause heartburn?
- Reflux was reported in 1.7% to 2.5% of people on Mounjaro vs 0.4% on placebo, and indigestion in 5% to 8% vs 3%.
- Why do GLP-1 drugs cause acid reflux?
- They slow stomach emptying, so food and acid stay in the stomach longer, which is a known risk factor for reflux.
- Does GLP-1 heartburn go away?
- Gut side effects are most common while the dose is being increased and often ease. Heartburn that persists, or comes with trouble swallowing or chest pain, needs medical review.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
Last reviewed November 11, 2026. Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.